Advertisement

Role of Patient Organisations

  • Nicola BedlingtonEmail author
  • Jan Geissler
  • François Houyez
  • Alison Lightbourne
  • Deborah Maskens
  • Valentina Strammiello
Chapter

Abstract

Please check all author names and their affiliations, and correct if necessary.

Keywords

Patient Involvement Patient Organisation Umbrella Organisation Orphan Medicinal Product Innovative Medicine Initiative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. ADAPTSMART. Accelerated development of appropriate patient therapies a sustainable, multi-stakeholder approach from research to treatment-outcomes (2016). http://adaptsmart.eu/. Accessed 17 Aug 2016.
  2. EATG. AIDS Treatment project. Press Conference. In: EATN (1996). http://www.eatg.org/wp-content/uploads/2016/05/1996vol5n6.pdf. Accessed 20 Nov 2016.
  3. CORD. Affiliate/Group. http://www.raredisorders.ca/cord-membership/#section-id-157 (2016). Accessed 16 Nov 2016.
  4. EmERGE. EmERGE mHealth platform. http://www.emergeproject.eu/. 2016. Accessed 07 Sept 2016.
  5. EPF. Health Technology Assessment: European Patients’ Forum seminar report, European Patients’ Forum. 2010. http://www.eu-patient.eu/globalassets/library/conferenceseminarreports/hta-seminar-2010-brussels-report.pdf. Accessed 15 Sept 2016.
  6. EPF. Patient involvement in Health Technology Assessment in Europe: results of the EPF survey. European Patients’ Forum. 2013. http://www.eu-patient.eu/globalassets/projects/hta/hta-epf-final-report2013.pdf. Accessed 16 Aug 2016.Google Scholar
  7. EPF. European Patients’ Forum (2016). www.eu-patient.eu. Accessed 15 Sept 2016.
  8. EUPATI. European Patients’ Academy on Therapeutic Innovation (2016a). http://www.patientsacademy.eu/. Accessed 16 Aug 2016.
  9. EUPATI. European Patients’ Academy. 2016b. https://www.eupati.eu. Accessed 16 Aug 2016.
  10. European Commission. High Level Pharmaceutical Forum—2005–2008—Final Report. European Commission. 2008. http://www.anm.ro/_/Final%20Conclusions%20and%20Recommendations%20of%20the%20High%20Level%20Pharmaceutical%20Forum.pdf. Accessed 18 Nov 2016.
  11. European Commission. Report on the public consultation on the modalities of stakeholder consultation in the future Health Technology Assessment Network, European Commission. 2012. http://ec.europa.eu/health/technology_assessment/docs/cons_hta_network_results_en.pdf. Accessed 06 Sept 2016.
  12. European Multiple Sclerosis Platform, European register for multiple sclerosis project report 2011–2014. 2016. http://www.emsp.org/wp-content/uploads/2015/06/140930-EUReMS-Report.pdf. Accessed 17 Aug 2016.
  13. EURORDIS. The voice of 12,000 patients—experiences and expectations of rare disease patients on diagnosis and care in Europe. 2009. http://www.eurordis.org/IMG/pdf/voice_12000_patients/EURORDISCARE_FULLBOOKr.pdf. Accessed 17 Nov 2016.
  14. EURORDIS. Access to orphan drugs (2016a). http://www.eurordis.org/content/access-orphan-drugs. Accessed 17 Nov 2016.
  15. EURORDIS, Eurordis Summer School (2016b). http://www.eurordis.org/summer-school. Accessed 15 Sept 2016.
  16. Health Equality Europe. Understanding Health Technology Assessment (HTA). Health equality Europe. 2008. http://img.eurordis.org/newsletter/pdf/nov-2010/58-1%20HEE%20Guide%20To%20HTA%20for%20Patients%20English.pdf. Accessed 15 Sept 2016.
  17. IAPO. International Alliance of Patients’ Organizations. www.iapo.org.uk. 2016. Accessed 15 Sept 2016.
  18. Marcus AD. Lessons from AIDS/HIV advocacy efforts. In: Health blog: the Wall Street Journal. 2011. http://blogs.wsj.com/health/2011/06/16/lessons-from-aidshiv-advocacy-efforts/. Accessed 16 Aug 2016.Google Scholar
  19. MedTech Europe. 2015 Priorities of the “Patient-MedTech Dialogue”. Focus on Medtech. 2015. http://medical.technology/newsletternews/762/86. Accessed 17 Aug 2016.
  20. NHC. The patient voice in value: the National Health Council patient-centered value model rubric. NHC. 2016. http://www.nationalhealthcouncil.org/sites/default/files/Value-Rubric.pdf. Accessed 18 Nov 2016.
  21. Pivik J, Rode E, Ward C. A consumer involvement model for Health Technology Assessment in Canada. Health Policy. 2004;69:253–68.CrossRefPubMedGoogle Scholar
  22. SEED. Shaping European Early Dialogues. http://www.earlydialogues.eu/has/. 2015. Accessed 31 Oct 2016.
  23. Wong-Rieger D. Patients as partners in HTA. 2013. http://www.ispor.org/meetings/neworleans0513/releasedpresentations/W20_Wong-Rieger.pdf. Accessed 16 Aug 2016.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  • Nicola Bedlington
    • 1
    Email author
  • Jan Geissler
    • 2
  • François Houyez
    • 3
  • Alison Lightbourne
    • 4
  • Deborah Maskens
    • 5
  • Valentina Strammiello
    • 6
  1. 1.European Patients’ Forum-EPFBrusselsBelgium
  2. 2.EUPATIFrankfurtGermany
  3. 3.EURORDISParisFrance
  4. 4.IAPOLondonUK
  5. 5.International Kidney Cancer CoalitionAmsterdamThe Netherlands
  6. 6.EPFBrusselsBelgium

Personalised recommendations